In last trading session, CRISPR Therapeutics AG (NASDAQ:CRSP) saw 1,597,967 shares changing hands with its beta currently measuring 2.33. Company’s recent per share price level of $94.17 trading at $2.7 or 3.02% at ring of the bell on the day assigns it a market valuation of $5.86 Billion. That closing price of CRSP’s stock is at a discount of -3.88% from its 52-week high price of $97.82 and is indicating a premium of 65.7% from its 52-week low price of $32.3. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.87 Million shares which gives us an average trading volume of 1.04 Million if we extend that period to 3-months.
For CRISPR Therapeutics AG (CRSP), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.3. Splitting up the data highlights that, out of 17 analysts covering the stock, 2 rated the stock as a Sell while none recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 11 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.96 in the current quarter.
Upright in the green today for gaining 3.02%, in the last five days CRSP remained trading in the green while hitting it’s week-highest on Wednesday, Jul 08 when the stock touched $97.82- price level, adding 3.74% to its value on the day. CRISPR Therapeutics AG’s shares saw a change of 54.62% in year-to-date performance and have moved 28.14% in past 5-day. CRISPR Therapeutics AG (NASDAQ:CRSP) showed a performance of 55.58% in past 30-days. Number of shares sold short was 3.84 Million shares which calculate 3.69 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $75.75 to the stock, which implies targetted prices is already lagging behind -19.56% to its current value. Analysts have been projecting $31 as a low price target for the stock while placing it at a high target of $105. It follows that stock’s current price would jump +11.5% in reaching the projected high whereas dropping to the targeted low would mean a loss of -67.08% for stock’s current value.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
Statistics highlight that CRISPR Therapeutics AG is scoring comparatively lower than the scores of other players of the relevant industry. The company added +56.04% of value to its shares in past 6 months, showing an annual growth rate of -490.6% while that of industry is 10.2. Apart from that, the company came raising its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to increase by 5% in the current quarter and calculating -150.8% decline in the next quarter. This year revenue growth is estimated to drop -94.2% from the last financial year’s standing.
11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $17.5 Million for the same. And 11 analysts are in estimates of company making revenue of $2.1 Million in the next quarter that will end in September 01, 2020. Company posted $3.94 Million of sales in current quarter a year earlier. Analysts are expecting this quarter sales to grow by 344.2%.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 54% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 134.1% while estimates for its earnings growth in next 5 years are of 0%
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
Insiders are in possession of 20.94% of company’s total shares while institution are holding 55.73% percent of that, with stock having share float percentage of 70.5%. Investors also watch the number of corporate investors in a company very closely, which is 350 institutions for CRISPR Therapeutics AG that are currently holding shares of the company. ARK Investment Management, LLC is the top institutional holder at CRSP for having 4.29 Million shares of worth $181.75 Million. And as of March 30, 2020, it was holding 6.92% of the company’s outstanding shares.
The second largest institutional holder is Versant Venture Management, LLC, which was holding about 4.21 Million shares on March 30, 2020. The number of shares represents firm’s hold over 6.79% of outstanding shares, having a total worth of $178.36 Million.
On the other hand, ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF are the top two Mutual Funds which own company’s shares. As of April 29, 2020, the former fund manager was holding 2566352 shares of worth $126.26 Million or 4.14% of the total outstanding shares. The later fund manager was in possession of 1.26 Million shares on April 29, 2020, making its stake of worth around $62.12 Million in the company or a holder of 2.04% of company’s stock.